Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update
Siegfried SegaertDepartment of Dermatology, University Hospital Leuven, BelgiumAbstract: Etanercept, a subcutaneously administered fully human soluble tumor necrosis factor (TNF) receptor, was initially approved for the treatment of psoriasis at a dose of 25 mg twice weekly in repeated 24-week cycle...
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2009
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/c3a4606f391a49e58df829dbcf40fbc6 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|